Breakthrough Alzheimer's Drug Shows Promising Results in Clinical Trials
A new Alzheimer's treatment has demonstrated remarkable success in Phase 3 clinical trials, slowing cognitive decline by 47% in patients with early-stage disease. The drug, developed by BioMed Innovations, could represent the most significant advance in Alzheimer's treatment in decades.
